Albifylline
Alternative Names: A 813138; HWA 138Latest Information Update: 18 Jul 1995
Price :
$50 *
At a glance
- Originator Aventis
- Class Xanthines
- Mechanism of Action Cell membrane permeability inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Septic shock
Most Recent Events
- 18 Jul 1995 Discontinued-I for Septic shock in Germany (Unknown route)
- 18 Jul 1995 Discontinued-I for Septic shock in USA (Unknown route)
- 09 Dec 1994 Phase-I clinical trials for Septic shock in Germany (Unknown route)